Aligos therapeutics appoints david perry as vice president of business development

South san francisco, calif., oct. 01, 2024 (globe newswire) -- aligos therapeutics, inc. (nasdaq: algs) a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced the appointment of david perry as vice president of business development, effective immediately.
ALGS Ratings Summary
ALGS Quant Ranking